|drug617||COVID-19 exposure Wiki||0.41|
|D002318||Cardiovascular Diseases NIH||0.10|
There are 3 clinical trials
There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti- inflammatory, anti-oxidative effects and their modulation of the intestinal microbiota. This randomized controlled trial seeks to evaluate the efficacy of the tannins based dietary supplement ARBOX in positive COVID-19 patients.
Description: defined as the time from first dose of polyphenol extract to hospital dischargeMeasure: Time to hospital discharge Time: Throughout the Study (Day 0 to Day 28)
Description: proportionMeasure: 28-day all-cause mortality Time: Throughout the Study (Day 0 to Day 28)
Description: proportionMeasure: invasive ventilation on day 28 Time: Throughout the Study (Day 0 to Day 28)
Description: mean differenceMeasure: Difference in Pro and antiinflammatory citoquine levels Time: day 1-14
Description: proportionMeasure: Negativization of COVID-PCR at day 14 Time: day 14
The aim of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) in patients infected with SARS-CoV-2. The specific objectives are to assess whether, in patients with mild and moderate forms of SARS-CoV-2, daily use of CBD 300 mg for fourteen days is capable of: i) decrease viral load; ii) modify inflammatory parameters, such as cytokines, measured from serum; iii) reduce clinical and emotional symptoms through daily clinical evaluation; iv) improve sleep; v) reduce hospitalization and worsen the severity of the disease; v) Monitor the possible adverse effects of CBD use in these patients.
Description: Deterioration in clinical status from mild/moderate to severe/critical over time during the study periodMeasure: Prevention of severe/critical stage of Covid19 Time: Up to 28 days
Description: Clinical CoVid19 symptoms Clinical improvementMeasure: Time to CoVid19 symptoms relief and number of participants with negative Clinical CoVid19 symptoms as assessed by CTCAE v5.0 Time: Up to 28 days
Description: Immune reactionMeasure: Change in proinflammatory cytokine concentration Time: Up to 28 days
Description: A qualitative CT analysis of parenchymal lung damage induced by COVID-19Measure: Describe the parenchymal lung damage induced by COVID-19 through a qualitative analysis with chest CT Time: 14 days
Description: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: Up to 28 days
Description: Time to clinical improvementMeasure: Time to clinical improvement with CTCAE v5.0 CoVid19 symptoms to 0 Time: Up to 28 days
Description: CoVid severity worseningMeasure: Number of participants that need hospitalisation Time: Up to 28 days
Description: MortalityMeasure: 28-day mortality Time: Up to 28 days
Description: Time to negative salivaMeasure: Time to positive-to-negative saliva 2019-n-CoV RT-PCR conversion Time: Up to 28 days
Description: Mean reduction in viral load (reduction of ≥1 log10) over time during the study periodMeasure: Reduction in viral load Time: Up to 28 days
Description: Brief measure for assessing generalized anxiety disorder (The GAD-7) and depression (PHQ-9)Measure: Brief measure for assessing generalized anxiety disorder and depression Time: Through study completion, over time during the study period (day 0-28)]
Description: Scores of the brief peanut butter olfactory test (Univ Florida)Measure: Increment of odor detection sensitivity Time: Through study completion, over time during the study period (day 0-28)]
HYPOTHESIS: The administration of vitamin D supplements to patients who have a positive diagnosis for SARS-Cov-2, acute pneumonia requiring hospital admission and vitamin D deficiency have a more favourable evolution than subjects not treated with vitamin D (placebo). This favourable evolution will translate into a reduction in mortality, fewer ICU admissions and fewer days of stay in hospital. OBJECTIVES: PRINCIPAL: To assess whether the group of patients receiving vitamin D supplements have a less severe evolution of their acute pneumonia, translated into lower mortality, than patients who do not receive that supplement. SECONDARY: 1) To determine the number of intensive care admissions and the number of days of admission in both groups (control group and intervention group). 2) To estimate the prevalence of Vitamin D deficiency in the patients studied and the effectiveness of its supplementation. 3) To establish the degree of complexity of each study group and carry out a cost-effectiveness study. METHODOLOGY: DESIGN: Clinical trial, randomized, placebo-controlled and double-blind, with two parallel groups The active treatment will be vitamin D (Hydroferol soft capsules of 0.266 mg). The placebo will consist of a tablet with the same external characteristics and with the same treatment scheme but which will not contain any vitamin D active ingredients.
Description: Mortality reductionMeasure: MORTALITY Time: At 21 days.
Description: Intensive care admissions reductionMeasure: Intensive care admissions Time: At 21 days
Description: Length of hospital stay reductionMeasure: Length of hospital stay Time: AT 21 DAYS
Description: To assess the prevalence of vitamin D deficiency at baselineMeasure: Prevalence of vitamin D deficiency Time: At baseline
Description: To calculate the incremental cost per event (mortality) avoidedMeasure: Incremental cost effectiveness ratio (ICER) Time: At 21 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports